Research for development of nobel type vaccine with cetylmanoside-modified liposomes

我们发现，修饰有十六烷基甘露糖苷（Man-MLV）的脂质体可能是一种有前途的候选佐剂，可能用于人类。本文制备了几种不同的脂质体，研究了脂质体的理化性质对脂质体佐剂性的影响。因此，具有直径为200 nm的刚性膜并用30mol%的十六烷基甘露糖苷修饰的脂质体显示出最大的活性来产生包封在脂质体中的抗BSA的特异性抗体。最有可能的是，脂质体通过补体受体介导的内吞作用将包封的抗原（BSA）有效地递送到吞噬细胞如巨噬细胞中，导致血清中特异性抗体滴度增加。此外，Man-MLV（30 mol %）与人全血孵育后显示出诱导外周血细胞释放细胞因子的能力。总之，Man-MLV（30 mol %）通过增加吞噬细胞对抗原的摄取以及刺激免疫系统，具有显著的诱导抗原特异性抗体的能力。

We showed that the liposomes which were modified with cetylmannoside (Man-MLV) could be one of promising candidates for the adjuvant, possible to use for human. We prepared some kinds of liposomes to study which physicochemical properties of the liposomes decide their adjuvant ability. Consequently, the liposomes that have rigid membrane, 200nm in a diameter and being modified with 30 mol % cetylmannoside, showed most activity to produce specific antibody against BSA encapsulated into the liposomes. It is most likely that the liposomes efficiently delivered the encapsulated antigen (BSA) into phagocytic cells such as macrophages via complement-receptor mediated endocytosis, resulting in increased the specific antibody titer in serum. In addition, the Man-MLV (30 mol %) showed the ability to induce cytokine release from peripheral blood cells following incubation with human whole blood. In conclusion, the Man-MLV (30 mol %) have remarkable ability to induce antigen-specific antibody by increasing uptake of the antigen by phagocytic cells as well as stimulating immune system.